<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068989</url>
  </required_header>
  <id_info>
    <org_study_id>1301011408</org_study_id>
    <nct_id>NCT02068989</nct_id>
  </id_info>
  <brief_title>Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus</brief_title>
  <official_title>Stress Hyperglycemia as an Indicator for Future Diabetes Mellitus: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that stress hyperglycemia is an indicator that a patient will develop type 2
      diabetes mellitus in the future. Subjects who are not diabetic are enrolled and blood
      glucose readings reviewed during their intensive care unit stay. All subjects are consented
      and have a HbA1C level drawn to determine if they have diabetes mellitus or not. They are
      then followed up in 1 year and the HbA1C repeated to determine if they have developed
      diabetes mellitus over the course.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percentage of Subjects with an HbA1c greater than or equal to 6.5%</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Stress Hyperglycemia</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Stress Hyperglycemic Group</arm_group_label>
    <description>Repeat HbA1C in 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Euglycemic Group</arm_group_label>
    <description>Repeat HbA1C in 1 year</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Intensive Care Unit admissions who are not known to be diabetic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted to the intensive care unit at the Yale New Haven Hospital St.
             Raphael Campus and Norwalk Hospital

        Exclusion Criteria:

          -  Patients with prior history of diabetes mellitus

          -  Elevated admission HbA1c (â‰¥6.5%)

          -  Age &gt;80 years

          -  Metastatic disease with expected life expectancy of less than 12 months

          -  Pregnancy or a woman who plans to become pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Atlas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale New Haven Health System Center for Healthcare Solutions</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathon Fine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwalk Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu Sharma, MBBS</last_name>
    <phone>2036801560</phone>
    <email>anu.sharma@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Atlas, MD</last_name>
    <phone>2037893103</phone>
    <email>stephen.atlas@ynhh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale New Haven Hospital St. Raphael Campus</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anu Sharma, MBBS</last_name>
      <phone>203-680-1560</phone>
      <email>anu.sharma@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Anu Sharma, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathon Fine, MD</last_name>
      <email>jonathon.fine@norwalkhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jonathon Fine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>February 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
